by MM360 Staff | Nov 19, 2020 | Featured News, Myeloma News
A new study published in Cancer Medicine demonstrates that Hypercalcemia is associated with poor rates of survival in patients with newly diagnosed myeloma (NDMM). The researchers retrospectively evaluated the prognostic impact and mechanism of hypercalcemia in 357...
by MM360 Staff | Nov 19, 2020 | Featured News, Myeloma News
Smoldering multiple myeloma (SMM) is a plasma cell disorder with the potential to evolve to multiple myeloma. Several risk stratification models have been used to identify patients at high risk who may be eleigible for early treaetment. In an article published today...
by MM360 Staff | Nov 18, 2020 | Featured News, Myeloma News
Cellectis announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM). Cellectis worked...
by MM360 Staff | Nov 14, 2020 | Featured News, Myeloma News
A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. The results from the BOSTON study demonstrate that the once-weekly...
by MM360 Staff | Nov 11, 2020 | Featured News, Myeloma News
GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products. MRD is increasingly used as an endpoint in clinical trials, and clonoSEQ has emerged as the premier test to reliably and accurately...
by MM360 Staff | Nov 4, 2020 | Featured News, Myeloma News
Allogene Therapeutics, announced that it will present data on ALLO-715, an anti-BCMA AlloCAR T therapy at the 62nd Annual Meeting of the American Society of Hematology (ASH), taking place virtually December 5 – 8, 2020. The oral presentation will include data on...
